Excessive drinking was responsible for an average of 255 deaths per day in the United States during 2011 to 2015.
A team of investigators sought to investigate the rate of resolution of Clostridioides difficile infection as well as safety associated with fecal microbiota transplantation in patients with liver cirrhosis.
Time to rebleeding was a significant predictor of mortality risk following an endoscopic variceal ligation procedure.
A systematic review and meta-analysis of observational studies was conducted to assess the prevalence of nonalcoholic fatty liver disease in the general population.
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
The FDA has lifted the clinical hold on 3 Investigational New Drug applications evaluating seladelpar (CymaBay Therapeutics) for the treatment of non-alcoholic steatohepatitis, primary biliary cholangitis and primary sclerosing cholangitis.
Recommendations are presented for testing and clinical management of health care personnel exposed to the hepatitis C virus in a US Centers for Disease Control and Prevention guidance report.
Routine hepatitis C virus testing at federally qualified health centers would be cost-effective and could improve outcomes for people with HCV infections.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
A team of investigators assessed outcomes associated with advanced liver fibrosis in patients with COVID-19 infection.
A team of investigators in Italy assessed outcomes in patients with both cirrhosis and COVID-19 infection.
A viral exposure signature can predict hepatocellular carcinoma (HCC) risk before clinical diagnosis among at-risk patients.
Failure to control oesophago-gastric variceal bleeding in patients with acute-on-chronic liver failure resulted in increased mortality risk.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
TDF therapy resulted in greater rates of elastographic reversion of cirrhosis in patients with chronic hepatitis B at year 5 compared with entecavir.
Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
A team of researchers conducted surveillance at a New York City hospital to assess the prevalence K pneumoniae.
The International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) has published consensus statements on the management of HE.
Researchers observed the presence of acute liver injury caused by COVID-19 in patients at multiple hospitals in China.
Women with non-alcoholic fatty liver disease have increased risks for maternal and neonatal complications.